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a b s t r a c t
Implantable cardioverter-deﬁbrillators (ICDs) are highly effective in reducing mortality related to
ventricular tachyarrhythmias (VTAs). Despite this beneﬁt, the occurrence of ICD shocks for VTAs in
patients with heart failure (HF) and depressed left ventricular function has been associated with adverse
outcomes. Patients with shocked VTAs are at an elevated risk of HF and death. While VTAs may be
markers for high-risk patients, it is possible that the harmful effects of electrical shocks and VTAs are
involved in HF progression and associated mortality. Some investigators have speculated that shocked
VTAs may activate signaling pathways in the molecular cascade of HF. We recently reported in an
experimental model of ventricular ﬁbrillation storm that multiple ICD shocks for recurrent ventricular
ﬁbrillation caused striking activation of Ca2þ/calmodulin-dependent protein kinase II, a validated
signaling molecule for HF. This review article describes the harmful effects of shocks and VTAs and
proposes that Ca2þ/calmodulin-dependent protein kinase II could connect shocked VTAs to adverse
outcomes.
& 2014 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.
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1. Introduction
The implantable cardioverter-deﬁbrillator (ICD) improves survival
in patients with a history of ventricular tachyarrhythmias (VTAs) or
those with heart failure (HF) and depressed left ventricular function
[1–4]. Despite this survival advantage, an important prognostic
association between ICD shocks for VTAs and adverse outcomes has
been demonstrated. Patients receiving an ICD shock for a sponta-
neous VTA are at increased risk of death [5,6]. Patients with more
ICD-shocked VTA episodes have a higher risk of death than patients
with less [6]. Electrical storm, a syndrome characterized by frequent
ICD shocks for multiple VTA episodes over a short period, has more
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serious prognostic consequences than VTAs unrelated to electrical
storm [7]. Electrical storm survivors are at high risk of early death
during the ﬁrst 3 months after the phenomenon [8,9]. These deaths
after ICD shocks for VTAs are commonly related to progressive HF
[5,6,8–11]. The association of shocked VTAs, HF, and mortality is clear,
although the underlying mechanisms remain uncertain. While VTA
episodes may be a marker for high-risk patients, there is the
possibility that harmful effects of VTAs, shocks, and their combination
are involved in HF progression and associated mortality. Some
investigators have speculated that ICD shocks for VTAs may activate
signaling pathways in the molecular cascade of HF [7,8,12,13]. We
recently created a chronic animal model of ventricular ﬁbrillation (VF)
storm in which left ventricular function deteriorated along with
striking activation of the intracellular Ca2þ-sensitive phosphorylating
enzyme Ca2þ/calmodulin-dependent protein kinase II (CaMKII) [14],
a validated signaling molecule causing HF. The aim of this paper is to
discuss the potential roles of shocks and VTAs in HF progression and
to present our proposal that CaMKII could connect shocked VTAs to
adverse outcomes.
2. Relationship among ICD shocks, substrate, and mortality
There is a strong correlation between ICD-shocked sponta-
neous VTAs and subsequent mortality [5,6]. Patients who receive
inappropriate shocks are also at an increased risk of mortality,
although the magnitude of this increase is smaller [5,6]. These
ﬁndings, together with the fact that the electrical shock may cause
myocardial damage and dysfunction, suggest that the ICD shock
itself is harmful, adversely affecting prognosis. However, this is
uncertain because the signiﬁcant correlation between shocks and
prognosis was not proved in subsequent clinical studies [15,16].
Whether shocks play an independent causal role or whether this
correlation is due solely to the underlying disease and arrhythmia
is strongly debated [17–19]. Recently, a retrospective study enrol-
ling a large number of ICD recipients, which was expected to
resolve this conﬂict, has been published. The ALTITUDE Survival by
Rhythm Study [20] demonstrated that patients who received
shocks for VTAs and atrial ﬁbrillation had an increased risk of
death and that there was no increased risk of mortality for those
with inappropriate shocks for sinus tachycardia or lead noise/
artifact/oversensing. This indicated that the adverse outcomes
after ICD shocks are more closely related to the underlying disease
and arrhythmia than to a harmful effect from the shock. Con-
versely, the importance of shocks on the prognosis has been
suggested by another pivotal clinical trial. The MADIT-RIT study
demonstrated that the programming of ICD therapies for VTAs of a
high rate or those with a prolonged delay in therapy was associated
with reductions in inappropriate therapy and mortality [21]. Reduc-
tions in the number of inappropriate shocks and the associated
reductions in total shock energy contributed in part to the mortality
beneﬁt in the high rate and delayed therapy group. The potential
roles of shocks and VTAs in HF progression, based on currently
available information obtained in clinical and experimental studies,
are discussed in the following sections.
2.1. Adverse effects of shocks
There is extensive literature on the harmful effects of electrical
shocks. Transient impairment of cardiac function, mild elevation of
cardiac troponin I levels, pathological changes (inﬂammation,
ﬁbrosis, calciﬁcation, macrophage inﬁltration, myocyte necrosis,
and interstitial edema), and ultrastructural alterations (mitochon-
drial swelling, loss of membrane integrity, and mitochondrial crest
disruption) have been demonstrated in human and animal studies
[22,23]. Many of these changes are linked to electroporation, the
disruption of cell membranes by an electrical shock [24]. Electro-
poration recovers over seconds to minutes, but cell membranes
are unable to recover following severe electroporation injury,
leading to cell death [24]. There is an assumption that irreversible
electroporation may be an important contributor to worsening HF
and poor outcomes [18]. However, this is unlikely because of
conﬂicting observations that electroporation caused by the shock
occurs at limited regions. Wang et al. examined the spatial
distribution and extent of electroporation by assessing propidium
iodide uptake in normal and infarcted rabbit hearts subjected to a
clinically relevant internal shock for sustained VF [25]. The
majority of propidium iodide staining was observed near the
shock electrode positioned at the right ventricular apex. The total
amount of propidium iodide staining was only 4% of the entire
ventricular mass, comparable to that between normal and
infarcted hearts. The hearts that were allowed to recover for
45 min after a deﬁbrillation shock showed substantial reduction
in propidium iodide staining. Nevertheless, the possibility that
electroporation may be more likely induced in failing myocardium
cannot be excluded. A study in patients with structural heart
disease, HF, and implanted ICD for primary and secondary pre-
vention of sudden cardiac death found that the instantaneous
emergence of local injury current on intracardiac right ventricular
electrograms, which was probably caused by electroporation,
during deﬁbrillation threshold testing was a predictor of HF
hospitalization and death [26]. Moreover, the local injury current
has recently been shown to appear after spontaneous appropriate
and inappropriate ICD shocks in some individuals [13]. More
studies are needed to clarify the effects of electroporation on
cardiac function in intact failing hearts, as well as the signiﬁcance
of local injury current following spontaneous ICD shocks on
prognosis in randomized clinical studies.
An ICD shock activates the sympathetic nervous system.
Systemic catecholamine levels increase three-fold and persist for
10 min following an ICD shock for induced VF in patients, which is
similar to an external shock for atrial ﬁbrillation [27]. It remains
uncertain whether transient increases in sympathetic activity are
associated with long-term effects, but it is clear that this is harmful
in some patients. Sympathetic stimulation can cause vasoconstric-
tion and amplify myocardial ischemia in the setting of decreased
coronary reserve [28]. Adrenergic surge plays a role in an electrical
storm [7]. Acute β-adrenergic receptor stimulation activates CaM-
KII, a validated signal for HF (see Section 4) in cardiomyocytes [29].
Additionally, a recent study using cardiomyocyte cultures reported
that electric shock caused an elevation of diastolic Ca2þ-levels,
probably via electroporation [30].
ICD shocks often cause psychiatric disorders. Patients have
decreased quality of life, including emotional dysfunction, during
the month following an ICD shock. Patients with anxiety and
depression have an activated hypothalamus–hypophysis–adrenal
axis and increased sympathetic activity [22]. Chronic sympathetic
activation could directly affect the myocardium and worsen
cardiac dysfunction. Chronic daily isoproterenol injection for
2 weeks causes cardiac dysfunction and dilatation in mice [31].
Mice overexpressing protein kinase A (PKA), β-adrenergic receptor
signaling molecule, develop dilated cardiomyopathy with reduced
cardiac contractility in association with aberrant intracellular
Ca2þ-homeostasis [32].
2.2. Adverse effects of ventricular tachyarrhythmias
The condition of myocardium at the time of VTA termination
may be an important determinant for patient outcome. As VF
accompanies myocardial ischemia, global ischemic stunning con-
tributes to myocardial depression after deﬁbrillation. Oxygen-
derived free radical formation and cytosolic Ca2þ-overload because
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of ischemia/reperfusion [33] might be involved in post-deﬁbrillation
stunning. Activation of Ca2þ-activated proteolytic enzyme calpains,
proteolysis of troponin I and α-actinin, acidosis-induced reduction in
myoﬁlament Ca2þ responsiveness, and tissue injury by activation of
nuclear factor-κB (NF-κB), a transcription factor of proinﬂammatory
response genes underlie contractile dysfunction associated with
ischemia/reperfusion [33,34].
Contractile dysfunction following deﬁbrillation occurs even in
the absence of ischemia or acidosis. Studies in perfused hearts
reported that VF caused contractile dysfunction without acidosis
or ATP depletion [35,36]. Electromechanical dissociation, the most
common cause of death during deﬁbrillation testing [37], occurs
even under the conditions of anesthesia and oxygenation. These
ﬁndings suggest that excess cytosolic Ca2þ during VF affects
contractile function, independent of ischemia/reperfusion, and
allows us to hypothesize that VTAs-induced Ca2þ-overload wor-
sens the substrate for HF by augmenting disease pathways. This
may be supported by clinical evidence that the association
between shocked VTAs and mortality is inﬂuenced by VTA
subtype. Increased mortality risk is greatest for VF and lowest
for slow ventricular tachycardia [18].
Experimental and clinical ﬁndings from the literature suggest
that activation of signaling and effector molecules by Ca2þ-over-
load resulting from VTAs in combination with shocks and asso-
ciated adrenergic surge may be responsible for HF progression and
adverse outcomes in patients with shocked VTAs.
3. Calcium signaling in an experimental model of VF storm
Intracellular Ca2þ-cycling is controlled by ion channels and
transporters, including L-type Ca2þ channel, sarcoplasmic
reticulum (SR) Ca2þ-release channel ryanodine receptor (RyR2),
SR Ca2þ-pump (SERCA2a), its regulatory protein phospholamban
(PLB), and Naþ–Ca2þ exchanger (NCX). Protein phosphorylation is
a major regulatory mechanism for contractility and relaxation
(Fig. 1). Phosphorylating mediators include PKA, CaMKII, and
protein kinase Cα (PKCα). Under physiological conditions,
CaMKII is activated by a fast heart rate and CaMKII-mediated
phosphorylation of these Ca2þ-handling proteins increases Ca2þ
inﬂux and SR Ca2þ-storage, leading to increased intracellular
systolic Ca2þ and increased contractility. PKA is activated by
β-adrenergic receptor agonists and catalyzes phosphorylation of
the same Ca2þ-handling proteins modiﬁed by CaMKII, but at
different amino acids. PKCα is activated downstream to a variety of
G-protein-coupled receptors such as angiotensin II receptor, α-
adrenoreceptor and endothelin receptor, and is activated by increased
intracellular Ca2þ concentrations ([Ca2þ]i). PKCα activation leads to
decreased activity of SERCA2a by phosphorylating inhibitor-1
(I-1). PKCα -mediated phosphorylation of I-1 leads to PLB depho-
sphorylation, resulting in reduced SR Ca2þ load and Ca2þ release,
causing reduced contractility [38]. While cardiac function is regulated
by these protein kinases, excess activity of PKA [32], CaMKII [39–41],
and PKCα [42] and the resulting hyperphosphorylation of these Ca2þ-
handling proteins are linked to mechanical dysfunction and
arrhythmias.
We examined the alterations in Ca2þ-signals and protein
phosphorylation in a rabbit model of VF storm (Fig. 2) [14]. This
animal model was developed from a rabbit model of chronic
complete atrioventricular block (CAVB). CAVB rabbits show biven-
tricular hypertrophy and electrophysiological features similar to
long QT syndrome including torsades de pointes-like arrhythmia,
VF, and sudden death [43,44]. CAVB rabbits equipped with ICDs
followed up for 80 days all showed cardiac hypertrophy, long QT,
Fig. 1. Regulation of intracellular Ca2þ cycling. β-Adrenergic activation of the cAMP-dependent protein kinase (PKA) directly phosphorylates L-type Ca2þ channel (LTCC),
Ca2þ-release channel (RyR2), and phospholamban (PLB), increasing the gain of excitation-contraction coupling. Faster heart rates increase the average [Ca2þ]i, which
activates Ca2þ/calmodulin-dependent protein kinase II (CaMKII). CaMKII can phosphorylate LTCC, RyR2, and PLB. Activation of the angiotensin-II receptor (AT-IIR) or α-
adrenoceptor (α-AR) activates phospholipase C (PLC), which, in turn, activates protein kinase Cα (PKCα). PKCα can directly phosphorylate protein phosphatase inhibitor-1 (I-
1), augmenting the activity of the protein phosphatase-1 (PP1) and causing hypophosphorylation of PLB. PLB hypophosphorylation inhibits SERCA2a function. PKA-
phosphorylated I-1 inhibits PP1, augmenting the PLB phosphorylation resulting from direct PKA action. The expression and activity of CaMKII and PKCα are upregulated in
human and animals with HF.
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and ICD-detected VF-episodes, followed by VF storm (deﬁned as
Z3 VF episodes per 24-h), which developed in approximately 50%
of CAVB rabbits. VF storm rabbits showed left-ventricular function
deterioration, along with striking activation of CaMKII and enhanced
expression of protein phosphatase. These alterations were associated
with notable changes: hyperphosphorylation of L-type Ca2þ channel
and RyR2 and dephosphorylation of PLB, a phosphorylation pattern
similar to ﬁndings in failing human and animal hearts [45]. These
prominent changes in VF storm rabbits were attributed in part to the
direct effects of repeated VF and deﬁbrillation. Indeed, VF induction
and deﬁbrillation 10 times over 1 h in baseline rabbits reproduced the
changes observed in CaMKII activation and PLB phosphorylation in VF
storm rabbits, but 10 shock pulses without VF induction did not. PKAα
catalytic subunit was decreased similarly in VF storm and non-storm
rabbits. PKA-dependent phosphorylation of myosin-binding protein C
and troponin I did reduce, but there was no difference between the VF
storm and non-storm rabbit groups. Neither PKCα catalytic subunit
expression nor PKCα activity were altered. These results suggest that
CaMKII, but not PKA or PKCα, plays a central pathophysiological role in
left ventricular dysfunction associated with VF storm in this animal
model.
4. CaMKII and heart failure progression
CaMKII is a multifunctional serine–threonine kinase, phosphor-
ylating target proteins. Under resting conditions, CaMKII is inac-
tive. A rise in intracellular Ca2þ stimulates binding of Ca2þ to
calmodulin (CaM), a ubiquitous Ca2þ-binding protein. The Ca2þ/
CaM complex activates CaMKII (Ca2þ/CaM-dependent activation).
With a sustained increase in Ca2þ/CaM or reactive oxygen species
(ROS), CaMKII transitions into a Ca2þ/CaM-autonomous active
enzyme after autophosphorylation at Thr286 or oxidation at
Met281/282 (Ca2þ/CaM-independent activation) [46,47]. This acti-
vation is maintained under normal Ca2þ concentrations, a feature
that has been regarded to be similar to a “memory” molecule [47].
Autophosphorylated and/or oxidized CaMKII that become consti-
tutively active participate in the disease pathway by phosphor-
ylating protein targets for excitation–contraction coupling and cell
survival, including ion channels and Ca2þ-handling proteins, and
transcription factors that drive hypertrophic and inﬂammatory
gene expression. CaMKII is now linked to the pathophysiology of a
variety of cardiac diseases including HF, myocardial infarction,
ischemia/reperfusion and cardiac arrhythmias, most of which have
Fig. 2. Rabbit model of VF storm. (A) Chemical AV node ablation and extracardiac ICD system implantation. (B) ICD parameters. The number of intervals to detect VF (NID)
and to redetect VF (NID redetect) was programmed to the maximum values available in the device, 120 of 160 and 30 of 40, respectively, to avoid inappropriate shocks for
torsades de pointes-like arrhythmias, which occur frequently in chronic AV rabbits. (C) An example of VF storm
(modiﬁed from Tsuji et al. [14]).
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been demonstrated by Anderson et al. and reviewed in their
excellent articles [45,47–49].
The expression and activity of CaMKII are increased in human and
animals with HF. CaMKII-overexpressing mice died prematurely with
HF phenotype [39–41]. Deletion of CaMKIIδ, a predominant cardiac
isoform, prevented transition from pressure overload-induced hyper-
trophy to HF in mice [50].
CaMKII triggers diverse, maladaptive cellular events essential to
HF development, including hypertrophy, inﬂammation, and cell
death. Excessive CaMKII activates hypertrophic genes by phos-
phorylating class II histone deacetylases and by derepressing
myocyte enhancer factor 2-dependent transcription [51]. CaMKII
mediates NF-κB activation to activate proinﬂammatory genes after
myocardial infarction [31] and ischemia/reperfusion [34]. Genetic
CaMKII inhibition attenuates adverse remodeling and protects
against HF after myocardial infarction in mice [31].
Excessive CaMKII also causes mitochondrial Ca2þ dysregulation
and activates the cell death pathway [49]. An increase in mito-
chondrial Ca2þ concentrations secondary to cytosolic Ca2þ over-
load depolarizes the membrane potential across the inner
membrane potential (Δψm), produces ROS, and activates mito-
chondrial permeability transition pore (mPTP) opening, followed
by the subsequent release of apoptosis-related proteins into the
cytosol [49]. CaMKII promotes Δψm depolarization and mPTP
opening in permeabilized rat myocytes [52]. A recent study has
found that CaMKII phosphorylates mitochondrial Ca2þ uniporter, a
mitochondrial Ca2þ entry channel, resulting in increased inward
current into the mitochondria. Mitochondrion-delimited CaMKII
inhibition prevented mPTP opening and Δψm depolarization and
diminished mitochondrial disruption and cell death in response to
ischemic/reperfusion injury in mice [53].
The effect of CaMKII on ion channels contributes to aberrant
intracellular Ca2þ homeostasis in HF. CaMKII-dependent hyper-
phosphorylation of RyR2 increases inappropriate diastolic Ca2þ
release from SR that promotes HF (because of loss of SR Ca2þ load)
and arrhythmogenic delayed afterdepolarizations. Pharmacologi-
cal CaMKII inhibition reduces the phosphorylation levels of RyR2
at both Ser2809 (PKA/CaMKII phosphorylation site) and Ser2815
(CaMKII site) and improves contractility along with reduced SR
Ca2þ leak and increased SR Ca2þ stores in failing human myo-
cardium [54]. Mice with constitutively phosphorylated RyR2 that
can be attributed to mutant S2814D have RyR2-mediated SR Ca2þ
leak and develop late onset cardiomyopathy [55]. Moreover,
knock-in mice with an inactivated Ser2814 phosphorylation site
are protected from HF development after transverse aortic con-
striction [56].
CaMKII phosphorylation of L-type Ca2þchannels alters channel
gating by increasing open probability. CaMKII increases the win-
dow current of ICa-L, increasing the probability of the channels
reopening during phase 2 action potential and predisposing to
early afterdepolarizations. Recently identiﬁed phosphorylation
sites of L-type Ca2þ channels include Ser1512 and Ser1570 of the
α-subunit CaV1.2 and Thr498 of the accessory β2a-subunit [57,58].
However, the relative relationship between these phosphorylation
sites and ICa-L changes remains unclear. Interestingly, a study using
rabbit ventricular myocytes overexpressing β2a demonstrated that
Thr498 phosphorylation reduced cell survival [59]. The authors
suggested that CaMKII phosphorylation of β2a could initiate a
pathological cascade of enhanced cellular Ca2þ entry causing
excessive SR Ca2þ release, leading to reduced cell survival.
CaMKII action on voltage-gated Naþ channel subunit NaV1.5
has also been implicated as a potent contributor to HF progression.
HF is associated with increased intracellular Naþ concentrations
([Naþ]i). The rise in [Naþ]i increases Ca2þ inﬂux via reverse model
NCX during systole and limits Ca2þ efﬂux via forward NCX during
diastole, leading to intracellular Ca2þ overload. Increases in
diastolic Ca2þ levels cause abnormal left ventricular relaxation
and diastolic dysfunction. The major pathway for increased Naþ
inﬂux is through Naþ channels. Although Naþ channels open and
close rapidly, a non-inactivated, persistent component of Naþ
current (INa-L) is enhanced in HF. In tachypacing-induced HF dogs,
the difference in INa-L before and after CaMKII inhibitor KN93
was greater in failing myocytes than in the control [60]. CaMKII
associates with and phosphorylates NaV1.5 at the linker between
domain I and II [61,62]. A recent study in rat ventricular myocytes
reported that an increase in INa-L caused an elevation in the
intracellular Ca2þ levels and activation of CaMKII, which, in turn,
phosphorylated NaV1.5, further promoting INa-L and subsequent
sodium-dependent Ca2þ overload [63].
5. Therapeutic consideration
From the results of larger-scale clinical trials demonstrating a
high frequency of HF and non-sudden cardiac death in patients
with shocked VTAs, optimization of HF therapy is strongly recom-
mended [5,7]. Because β-blockers, angiotensin-converting enzyme
inhibitors, angiotensin-receptor blockers, and spironolactone
reduce cellular Ca2þ load and ROS production, these HF medications
are likely to possess CaMKII inhibitory actions. This notion, although
not proven, might be supported by some experimental studies.
Metoprolol reverses the hyperphosphorylation of RyR2, restores the
stoichiometry of the RyR2macromolecular complex, and normalizes
single-channel function [64]. The angiotensin-receptor blocker val-
sartan restores SR function along with attenuation of RyR2 hyper-
phosphorylation and a decrease in abnormal SR Ca2þ-leak [65].
Therapeutic approaches targeting leaky RyR2 and INa-L have
recently emerged. RyR2 stabilizers JTV-519 and the more speciﬁc
analog S107 reduce SR Ca2þ leak by increasing the binding afﬁnity
for FKBP12.6 to RyR2 [66,67], whereas dantrolene, a therapeutic
agent for malignant hyperthermia, reduces SR Ca2þ leak by correct-
ing domain unzipping [68]. RyR2 stabilization with these agents
improves contractile function in dogs with HF [69]. Carvedilol [70]
and INa-L blocker ranolazine (not available in Japan) [71] have been
demonstrated to reduce RyR2 single-channel open probability. Low-
dose carvedilol prevents Ca2þ leak via RyR2 stabilization in HF dogs
[72]. Inhibition of INa-L with ranolazine exerts beneﬁcial effects on
systolic and diastolic HF in experimental models [73]. These agents
might also mitigate CaMKII overactivity by improving aberrant Ca2þ
homeostasis. In clinical situations where interventions targeting
CaMKII are not available, maximization of both conventional and
newly developed HF regimes should be underscored for the manage-
ment of ICD patients at risk.
6. Conclusions
Based on our ﬁndings using a chronic animal model in vivo that
repeated VF and deﬁbrillation, not shocks, are associated with
striking CaMKII activation, together with accumulating evidence
that CaMKII is crucially involved in cellular processes for HF, it is
conceivable that CaMKII activation contributes to HF progression
and associated mortality in patients with shocked VTAs. Develop-
ment of cardiospeciﬁc CaMKII inhibitory molecules with safe drug-
like properties is desirable and necessary for conﬁrming the
efﬁcacy on the HF phenotype, as well as clarifying this notion in
diseased human hearts in further studies.
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